In a clinical study carried out in Manaus, in which species L. (V.) guyanensis is predominant, there was low efficacy of the drug given to 26 patients with cutaneous leishmaniasis (CL) for 20 days, who also reported adverse events such as diarrhea in 60%, abdominal pain in 28%, and headache and nausea in 12% of the cases 11.